Loading...

New MS drug in spotlight after patient is diagnosed with deadly brain infection

Loading...
New MS drug in spotlight after patient is diagnosed with deadly brain infection - Hallo friend HEALTHY LIVING, In the article you read this time with the title New MS drug in spotlight after patient is diagnosed with deadly brain infection, we have prepared well for this article you read and download the information therein. hopefully fill posts items ENTERTAINMENT, items FITNES, items HEALTHY, items HEALTHY FOOD, items HEALTHY LIVING, items HOW HEALTHY, we write this you can understand. Well, happy reading.

Title : New MS drug in spotlight after patient is diagnosed with deadly brain infection
link : New MS drug in spotlight after patient is diagnosed with deadly brain infection

READ ALSO


New MS drug in spotlight after patient is diagnosed with deadly brain infection

RT | May 28, 2017

A new multiple sclerosis drug is under investigation after a patient who received it was diagnosed with a deadly brain disease.

The patient was reportedly treated with the drug Tysabri from Biogen for three years before receiving a single dose of the new drug Ocrevus by Roche in April. The subject later developed a rare brain infection called Progressive Multifocal Leukoencephalopathy (PML) which often results in “serious disability or death”.

Roche said it is investigating the cause of the infection with the patient’s previous diagnosis for John Cunningham virus being considered as a possible source.

The Swiss drugmaker acknowledged that, while there were no cases of PML recorded during its trials of Ocrevus, patients taking the drug were warned that there was a possible risk of developing a serious infection.

The risk is associated with all MS drugs that suppress the immune system. Dozens of patients undergoing treatment with Tysabri have been diagnosed with PML in the past, Reuters reports.

The US Food and Drug Administration (FDA) approved Tysabri for use in the country in March. This follows the regulator’s decision to take the drug off the market in 2005 after three patients involved in a clinical trial developed PML. Tsyabri was later reinstated with additional guidelines after users, for whom it was effective, demanded its return.

Roche claims the diagnosis was reported as a carry-over from Tysabri, otherwise known as natalizumab, by the patient’s physician. Tysabri manufacturer Biogen’s statement on the matter makes no mention of a possible connection to its drug.

"Biogen is aware that a patient taking Ocrevus has been diagnosed with PML, and we are currently assessing the information to confirm the reported PML," Biogen spokesman Matt Fearer told Reuters.

 RELATED:

Loading...


thus Article New MS drug in spotlight after patient is diagnosed with deadly brain infection

that is all articles New MS drug in spotlight after patient is diagnosed with deadly brain infection This time, hopefully can provide benefits to all of you. Okay, see you in another article posting.

You now read the article New MS drug in spotlight after patient is diagnosed with deadly brain infection with the link address https://healthylivingsimple.blogspot.com/2017/05/new-ms-drug-in-spotlight-after-patient.html

Subscribe to receive free email updates:

0 Response to "New MS drug in spotlight after patient is diagnosed with deadly brain infection"

Post a Comment

Loading...